Research goals for folate and related B vitamin in Europe

European Journal of Clinical Nutrition

Volumn 60, Issue 2, 2006, Pages 287-294

  Finglas, Paul M ^a   de Meer, K ^b   Molloy, A ^c   Verhoef, P ^d   Pietrzik, K ^e   Powers, H J ^f   van der Straeten, D ^g   Jagerstad M ^h   Varela Moreiras, G ⁱ   van Vliet, T ^j   Havenaar, R ^j   Buttriss, J ^k   Wright, A J A ^a  

^a INSTITUTE OF FOOD RESEARCH   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d WAGENINGEN UNIVERSITY   (Netherlands)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g GHENT UNIVERSITY   (Belgium)

^h SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

ⁱ UNIVERSIDAD SAN PABLO CEU   (Spain)

^j TNO   (Netherlands)

^k BRITISH NUTRITION FOUNDATION   (United Kingdom)

more..

Author keywords

Cancer; Folate; Food; Fortification; Homocysteine; Neural tube defect

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; VITAMIN B GROUP;

ARTICLE; BIOAVAILABILITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; COST BENEFIT ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; ELDERLY CARE; ENZYME POLYMORPHISM; FEASIBILITY STUDY; FOOD ANALYSIS; FOOD BIOTECHNOLOGY; FOOD COMPOSITION; GENE INTERACTION; HEALTH HAZARD; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IN VIVO STUDY; MALABSORPTION; MORBIDITY; NEURAL TUBE DEFECT; NUTRITIONAL STATUS; NUTRITIONAL VALUE; OSTEOPOROSIS; PATIENT COMPLIANCE; PREGNANCY; PREVALENCE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; STOMACH PH; UTERINE CERVIX CANCER; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

BIOLOGICAL AVAILABILITY; FOLIC ACID; FOOD TECHNOLOGY; FOOD, FORTIFIED; HUMANS; HYPERHOMOCYSTEINEMIA; INTESTINAL ABSORPTION; NEURAL TUBE DEFECTS; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 33645279888     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602315     Document Type: Article

References (65)

1. Afman LA, Trijbels FJM, Blom HJ (2003). The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans. J Nutr 133, 75-77.
2. Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M et al. (2002). Blinded comparison of folic acid and placebo in patients with ischemic heart disease: An outcome trial. Circulation 106, 3642 (abstract).
3. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H et al. (1999). Prevention of neural tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 341, 1485-1490.
4. Botto LD, Lisi A, Robert-Gnansia E, Erickson JD, Vollset SE, Mastroiacovo P et al. (2005). International retrospective cohort study of neural tube defects in relation to folic acid recommendations: Are the recommendations working? BMJ, doi: 19.1136/bmj.38336.664352.82 (published 18 February 2005).
5. Brouwer IA, van Dusseldorp M, West CE, Steegers-Theunissen RPM (2001). Bioavailability and bioefficacy of folate and folic acid in man. Nutr Res Rev 14, 267-293.
6. Buttriss J (2005). Strategies designed to increase awareness about folates and health, and to increase folate intake: A review. Trends Food Sci Technol 16, 246-252.
7. Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkirke NJ, Watkins WM (2005). Reduction of the efficacy of antifolate antimalarial theraphy by folic acid supplementation. Am J Trop Med Hyg 73, 166-170.
8. Choi S-W, Mason JB (2000). Folate and carcinogenesis: An integrated scheme. J Nutr 130, 129-132.
9. Choumenkovitch SF, Selhub J, Wilson PWF, Rader JI, Rosenberg IH, Jacques PF (2002). Folic acid intake from fortification in United States exceeds predictions. J Nutr 132, 2792-2798.
10. Cuskelly GJ, McNulty H, Scott JM (1996). Effect of increasing dietary folate on red-cell folate: Implications for prevention of neural tube defects. Lancet 347, 657-659.
11. Czeizel AE, Dudas I (1992). Prevention of the first occurrence of neural tube defects by periconceptual vitamin supplementation. New Engl J Med 327, 32-35.
12. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM (1995). Folate levels and neural tube defects. Implications for prevention. JAMA 274, 1698-1702.
13. Daly S, Mills JL, Molloy AM, Conley M, Lee YJ, Kirke PN et al. (1997). Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet 350, 1666-1669.
14. de la Vega A, Salicrup E, Verdiales M (2002). A nationwide program for the use of preconceptional folic acid to prevent the development of open neural tube defects. Who is really using folic acid? Puerto Rico Health Sci J 21, 7-9.
15. de Meer K, Pietrzik K, Finglas PM (2004). Meta-analysis of results from human intervention studies investigating folate absorption and effects on homocysteine. In Brzozowska A, Finglas PM, Wright D, Araucz M (eds). First International Conference on Folates - Analysis, Bioavailability and Health. Warsaw Agricultural University Press: Warsaw. pp. 121-122.
16. de Meer K, Smulders YM, Dainty JR, Smith DEC, Kok RM, Stehouwer CDA et al. (2005). Effect of [6S]5-methyltetrahydrofolate or folic acid supplementation on absorption and initial elimination of folate in young and elderly adults. Euro J Clin Nutr (in press).
17. Devlin AM, Ling E-H, Peerson JM, Fernando S, Clarke R, Smith AD et al. (2000). Glutamate carboxypeptidase II: A polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet 9, 2837-2844.
18. Finglas PM, Wright AJA, Wolfe CA, Hart DJ, Wright DM, Dainty JR (2003). Is there more to folates than neural-tube defects? Proc Nutr Soc 62, 591-598.
19. French AE, Grant R, Weitzman S, Ray JG, Vermeulen MJ, Sung L et al. (2003). Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Ther 74, 288-294.
20. Giovannucci E (2002). Epidemiologic studies of folate and colorectal neoplasia: A review. J Nutr 132, 2350S-2355S.
21. Gregory JF (1997). Bioavailability of folate. Eur J Clin Nutr 51 (Suppl 1), S54-S59.
22. Gregory JF, Quinlivan EP (2002). In vivo kinetics of folates. Annu Rev Nutr 22, 199-220.
23. Gregory JF, Quinlivan EP, Davis SR (2005). Integrating the issues of folate bioavailability, intake and metabolism in the era of fortification. Trends Food Sci Technol 16, 229-240.
24. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY (2001). Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285, 2981-2986.
25. Institute of Medicine (2000). Dietary Reference Intakes for Thiamine, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, pantothenic acid, Biotin and Choline. National Academy Press: Washington, DC.
26. Jackson MJ (1997). The assessment of bioavailability of micronutrients: introduction. Eur J Clin Nutr 51 (Suppl), S1-S2.
27. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenburg IH (1999). The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340, 1449-1454.
28. Johanning GL, Heimburger DC, Piyathilake CJ (2002). DNA methylation and diet in cancer. J Nutr 132, 3814S-3818S.
29. Kim Y-I (2004). Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 80, 1123-1128.
30. Koebnick C, Heins UA, Hoffmann I, Dagnelie PC, Leitzmann C (2001). Folate status during pregnancy in women is improved by long-term high vegetable intake compared with the average western diet. J Nutr 131, 733-739.
31. Lamers Y, Prinz-Langenohl R, Moser R, Pietrzik K (2004). Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. Am J Clin Nutr 79, 473-478.
32. Lin Y, Dueker SR, Follett JR, Fadel JG, Arjomand A, Schneider PD et al. (2004). Quantitation of in vivo human folate metabolism. Am J Clin Nutr 80, 680-691.
33. Lopez-Camelo JS, Orioli IM, Dutra M, Nazer-Herrera J, Rivera N, Ojeda ME et al. (2005). Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet Part A 135A, 120-125.
34. March of Dimes Birth Defects Foundation (2001). Folic Acid and the Prevention of Birth Defects. A National Survey of Pre-pregnancy Awareness and Behaviour Among Women of Childbearing Age 1995-2001. March of Dimes Birth Defects Foundation: White Plains, NY.
35. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al. (2004). Homocysteine as a predictive factor for hip fracture in older patients. N Engl J Med 350, 2042-2049.
36. Melse-Boonstra A, Lievers KJA, Blom HJ, Verhoef P (2004a). Bioavailability of polyglutamyl folic acid relative to that of monoglutamyl folic acid in subjects with different genotypes of the glutamate carboxypeptidase II gene. Am J Clin Nutr 80, 700-704.
37. Melse-Boonstra A, Verhoef P, West C (2004b). Quantifying folate bioavailability: A critical appraisal of methods. Curr Opin Clin Nutr Metab Care 7, 539-545.
38. Miller M, Bower C, payne J, Serna P (2000). Folate-related knowledge and practices of Western Australian women before and during pregnancy. Teratology 62, 367.
39. Mills JL, von Kohorn I, Conley MR, Zeller JA, Cox C, Williamson RE et al. (2003). Low vitamin B12 concentrations in patients without anaemia: the effect of folic acid fortification of grain. Am J Clin Nutr 77, 1474-1477.
40. Morris MC, Evans DA, Bienias JL, Tangney CC, Hebert LE, Scherr PA et al. (2005). Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol 62, 641-645.
41. MRC Vitamin Study Reseach Group (1991). Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 338, 131-137.
42. Pentieva K, McNulty H, Reuchert R, Ward M, Strain JJ, McKillop DJ (2004). The short-term bioavalabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men. J Nutr 134, 580-585.
43. Persad VL, van den Hof MC, Dube JM, Zimmer P (2002). Incidence of open neural tube defects in Nova Scotia after folic acid fortification. Canad Med Assoc 1167, 255-256.
44. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ (2005). Biochemical indicators of B vitamin status in the US population after folic acid fortification: Results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr 82, 442-450.
45. Quinlivan EP, Gregory JF (2003). Effect of food fortification on folic acid intake in the United States. Am J Clin Nutr 77, 221-225.
46. Rampersaud GC, Bailey LB, Kauwell GPA (2002). Relationship of folate to colorectal and cervical cancer: Review and recommendations for practitioners. J Am Diet Assoc 102, 1273-1282.
47. Ray JG, Langman LJ, Mamdani MM, Cole DEC (2005). Absence of effect of folic acid flour fortification on anticonvulsant drug levels. Am J Med 118, 444-445.
48. Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE (2002). Association of neural tube defects and folic acid fortification in Canada. Lancet 360, 2047-2048.
49. Sanderson P, McNulty H, Mastroiacovo P, McDowell FW, Melse-Boonstra A, Finglas PM et al. (2003). Folate bioavailability: UK Food Standards Agency workshop report. Br J Nutr 90, 473-479.
50. Sauberlich HE, Kretsch MJ, Skala JH, Johnson HL, Taylor PC (1987). Folate requirement and metabolism in nonpregnant women. Am J Clin Nutr 46, 1016-1028.
51. Scott J, Rebeille F, Fletcher J (2000). Folic acid and folates: The feasibility for nutritional enhancement in plant foods. J Sci Food Agr 80, 795-824.
52. Sybesma W, Starrenburg M, Kleerebezem M, Mierau I, de Vos WM, Hugenholtz J (2003). Increased production of folate by metabolic engineering of Lactococcus lactic. Appl Environ Microbiol 69, 3069-3076.
53. Takacs P, Rodriguez L (2005). High folic acid levels and failure of single-dose methotrexate treatment in ectopic pregnancy. Int J Gynecol Obstet 89, 301-302.
54. The Arabidopsis Genome Initiative (2000). Analysis of the genome sequence of the flowering plant Arabidopsis thaliana. Nature 408, 796-815.
55. Toole JF, Malinow MR, Chambless LE, Scence JD, Pettigrew LC, Howard VJ et al. (2004). Lowering homoxcysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. JAMA 291, 565-575.
56. Ubbink JB (2001). What is a desirable homocysteine level?. In: Carmel R, Jacobsen DW (eds.) Homocysteine in Health and Disease Chapter 40. Cambridge University Press: Cambridge.
57. van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF, van der Klift M, de Jonge R, Lindemans J et al. (2004). Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350, 2033-2041.
58. Van Oort FV, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB et al. (2003). Folic acid reduction of plasma homocysteine concentrations in older aldults: A dose-response study. Am J Clin Nutr 77, 1318-1323.
59. Vargas-Martinez C, Ordovas JM, Wilson PW, Selhub J (2002). The glutamate carboxypeptidase gene II (C > T) polymorphism does not affect folate status in the Framingham Offspring cohort. J Nutr 132, 1176-1179.
60. Verwei M, Arkbage K, Mocking H, Havenaar R, Groten J (2004). The binding of folic acid and 5-methyltetrahydrofolate to folate-binding proteins during gastric passage differs in a dynamic in vitro gastrointestinal model. J Nutr 134, 31-37.
61. Wald NJ (2004). Folic acid and the prevention of neural tube defects. N Engl J Med 305, 101-103.
62. Wild J, Sutcliff M, Schorah CJ, Levene MI (1997). Prevention of neural-tube defects. Lancet 350, 30-31.
63. Wright AJA, Finglas PM, Dainty JR, Wolfe CA, Hart DJ, Wright DM et al. (2005). Differential kinetic behaviour and distribution for pteroylglutamic acid and reduced folates: A revised hypothesis of the primary site of PteGlu metabolism in humans. J Nutr 135, 619-623.
64. Yang TL, Hung J, Caudill MA, Urrutia TF, Alamilla A, Perry CA et al. (2005). A long-term controlled folate feeding study in young women supports the validity of the 1.7 multiplier in the dietary folate equivalency equation. J Nutr 135, 1139-1145.
65. Yu J, Hu SN, Wang J, Wong GKS, Li SG, Liu B et al. (2002). A draft sequence of the rice genome (Oryza saliva L. ssp indica). Science 296, 79-92.